- Home
- MYO vs HOWL Comparison
MYO vs HOWL Comparison
Compare MYO & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- HOWL
- Stock Information
- Founded
- MYO 2004
- HOWL 2017
- Country
- MYO United States
- HOWL United States
- Employees
- MYO N/A
- HOWL N/A
- Industry
- MYO Industrial Specialties
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- MYO Health Care
- HOWL Health Care
- Exchange
- MYO Nasdaq
- HOWL Nasdaq
- Market Cap
- MYO 44.6M
- HOWL 47.1M
- IPO Year
- MYO 2017
- HOWL 2021
- Fundamental
- Price
- MYO $0.96
- HOWL $1.31
- Analyst Decision
- MYO Strong Buy
- HOWL Strong Buy
- Analyst Count
- MYO 3
- HOWL 5
- Target Price
- MYO $8.17
- HOWL $7.20
- AVG Volume (30 Days)
- MYO 2.1M
- HOWL 135.8K
- Earning Date
- MYO 11-05-2025
- HOWL 11-06-2025
- Dividend Yield
- MYO N/A
- HOWL N/A
- EPS Growth
- MYO N/A
- HOWL N/A
- EPS
- MYO N/A
- HOWL N/A
- Revenue
- MYO $40,760,091.00
- HOWL N/A
- Revenue This Year
- MYO $25.69
- HOWL N/A
- Revenue Next Year
- MYO $23.52
- HOWL N/A
- P/E Ratio
- MYO N/A
- HOWL N/A
- Revenue Growth
- MYO 93.08
- HOWL N/A
- 52 Week Low
- MYO $0.92
- HOWL $0.60
- 52 Week High
- MYO $7.17
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- MYO 24.94
- HOWL 51.06
- Support Level
- MYO $0.96
- HOWL $1.29
- Resistance Level
- MYO $1.17
- HOWL $1.40
- Average True Range (ATR)
- MYO 0.07
- HOWL 0.07
- MACD
- MYO 0.03
- HOWL -0.00
- Stochastic Oscillator
- MYO 5.82
- HOWL 54.76
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.